Filing Flows

Filing Flows › Companies › Profound Medical › Report card

Profound Medical earnings report card

Every report on file against what analysts and the company itself expected, and what the stock did

Beat rate3 of 5 reports beat the EPS estimate

Profound Medical (PROF) beat the analysts' EPS estimate in 3 of its last 5 reports (60%), by +8.5% on average. On report days the stock moved 5.9% in either direction on median (largest 29.0%), rising 40% of the time; after a beat it rose 33% of the time.

Beat rate60% of 5
Average surprise+8.5%
Median move on the day±5.9%
Rose on the day40%

Report by report

QuarterReportedEPS est.EPS reportedSurpriseRevenue reportedStock, the dayvs market
Q3 2026Nov 5, 2026−$0.20−$0.21-7.7%$9.8M+0.7%+4.8%
Q2 2026Aug 6, 2026−$0.24−$0.26-7.2%$2.5M-7.3%-7.7%
Q1 2026May 7, 2026−$0.25−$0.19+25.2%$5.3M-5.1%-5.6%
Q4 2025Mar 5, 2026−$0.27−$0.27+1.2%$6.0M-29.0%-27.1%
Q3 2025Nov 13, 2025−$0.38−$0.26+30.9%$5.3M+5.9%+7.5%

Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. The stock's move is close to close around the report date (the close before it to the close of the session after), against SPY for the market column.

Charts

Profound Medical: EPS reported against the estimateProfound Medical: EPS reported against the estimateEstimateReported−$0.38−$0.26Q3 2025−$0.27−$0.27Q4 2025−$0.25−$0.19Q1 2026−$0.24−$0.26Q2 2026−$0.20−$0.21Q3 2026
Latest (Q3 2026): Estimate −$0.20, Reported −$0.21.
PROF: the stock's move on each report dayPROF: the stock's move on each report dayQ3 2026+0.7%Q2 2026-7.3%Q1 2026-5.1%Q4 2025-29.0%Q3 2025+5.9%
Close to close around the report, from the daily price history.

The earnings-day move

Over 5 reports the stock moved 5.9% on median on the day (close to close), the largest move 29.0%.

After a beat the stock rose 33% of the time (3 beats); after a miss it fell 50% of the time (2 misses).

The next report: what to expect → Profound Medical: every quarter →

Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.